The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index; 29 of the 41 sources its claims cite were checked for support.
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
Open accessAbstract
Outcomes are poor in triple-class-exposed (TCE) relapsed and refractory multiple myeloma (R/RMM). In the phase 3 KarMMa-3 trial, patients with TCE R/RMM and 2 to 4 prior regimens were randomized 2:1 to idecabtagene vicleucel (ide-cel) or standard regimens (SRs). An interim analysis (IA) demonstrated significantly longer median progression-free survival (PFS; primary end point; 13.3 vs 4.4 months; P < .0001) and higher overall response rate (ORR) with ide-cel vs SRs. At final PFS analysis (median follow-up, 30.9 months), ide-cel further improved median PFS vs SRs (13.8 vs 4.4 months; hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.38-0.63). PFS benefit with ide-cel vs SRs was observed regardless of number of prior lines of therapy, with greatest benefit after 2 prior lines (16.2 vs 4.8 months, respectively). ORR benefit was maintained with ide-cel vs SRs (71% vs 42%; complete response, 44% vs 5%). Patient-centric design allowed crossover from SRs (56%) to ide-cel upon progressive disease, confounding overall survival (OS) interpretation. At IA of OS, median was 41.4 (95% CI, 30.9 to not reached [NR]) vs 37.9 (95% CI, 23.4 to NR) months with ide-cel and SRs, respectively (HR, 1.01; 95% CI, 0.73-1.40); median OS in both arms was longer than historical data (9-22 months). Two prespecified analyses adjusting for crossover showed OS favoring ide-cel. This trial highlighted the importance of individualized bridging therapy to ensure adequate disease control during ide-cel manufacturing. Ide-cel improved patient-reported outcomes vs SRs. No new safety signals were reported. These results demonstrate the continued favorable benefit-risk profile of ide-cel in early-line and TCE R/RMM. This trial was registered at www.ClinicalTrials.gov as #NCT03651128.
Overview
CoChat Summary
## TL;DR
In the preplanned final KarMMa-3 analysis with 30.9 months median follow-up, ide-cel continued to outperform standard regimens in triple-class-exposed relapsed/refractory multiple myeloma, with median PFS 13.8 vs 4.4 months and ORR 71% vs 42%. Overall survival was confounded by crossover, but crossover-adjusted analyses showed a trend favoring ide-cel, and safety remained consistent with prior reports.
## Key findings
- Median PFS was 13.8 months with ide-cel vs 4.4 months with standard regimens (HR 0.49; 95% CI, 0.38-0.63) at 30.9 months median follow-up.
- PFS benefit was seen across prior lines of therapy, with median PFS of 16.2 vs 4.8 months after 2 prior lines, 13.6 vs 3.4 months after 3 prior lines, and 11.2 vs 4.8 months after 4 prior lines.
- ORR was 71% with ide-cel vs 42% with standard regimens; CR rate was 44% vs 5%, and MRD-negative CR rate in evaluable patients was 35% vs 2%.
- Median OS was 41.4 months with ide-cel vs 37.9 months with standard regimens (HR 1.01; 95% CI, 0.73-1.40), but crossover-adjusted sensitivity analyses favored ide-cel (HR 0.72 and 0.87 in two prespecified models; post hoc IPCW HR 0.74).
## Methods
- KarMMa-3 was an international, randomized, open-label phase 3 trial in patients aged ≥18 years who had received 2 to 4 prior antimyeloma therapies including daratumumab, an immunomodulatory agent, and a proteasome inhibitor, with progressive disease within 60 days of last prior therapy.
- 386 patients were randomized 2:1 to ide-cel (n=254) or one of 5 investigator-selected standard regimens (n=132); after protocol amendment, crossover from standard regimens to ide-cel was allowed upon IRC-confirmed progression.
- Primary analysis was PFS by blinded independent review committee in the ITT population; secondary analyses included ORR, OS, MRD-negative CR, PFS2, HRQOL, and safety, with time-to-event outcomes analyzed by Kaplan-Meier and Cox models and OS sensitivity analyses adjusting for crossover.
## Limitations
- The paper states that the crossover design confounded OS interpretation.
- The text also notes that some bridging therapy may have insufficiently controlled disease before ide-cel infusion, contributing to early deaths; this is an evidence-based concern evident from the trial conduct and early-death pattern.
- No additional limitations are stated in the paper beyond prior reported KarMMa-3 limitations and crossover-related OS confounding.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
16 Valid · 0 Not valid · 2 Not checked · 62 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Management of relapsed MM remains challenging; patients are becoming triple-class exposed (TCE) earlier in their treatment course, 4-8 with no standard of care for early TCE relapsed and refractory MM (R/RMM).”
What the sources say
- Not checked — no full text of the sourcecites [4] Dimopoulos, 2022, Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma, Clin Lymphoma Myeloma Leuk source
- Not checked — no full text of the sourcecites [5] Chari, 25-27 2021 source
- Partly supportedcites [6] Gandhi, 2019, Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy, Leukemia sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes limited treatment options and poor outcomes after progression on CD38-targeted therapy. It does not establish that there is no standard of care specifically for patients who become triple-class exposed early in their treatment course. (LLM, conf=0.80)
- Partly supportedcites [7] Mateos, 2022, LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma, Leukemia sourceExperimental — accuracy not yet measured
The Discussion says there is no well-established real-world standard-of-care treatment for triple-class-exposed patients with relapsed/refractory multiple myeloma. However, the study focuses on heavily pretreated patients, and the cited passages do not establish that conclusion specifically for patients who become triple-class exposed early in treatment. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [8] Kumar, 2022, Treatment patterns and outcomes of patients with triple-class exposed relapsed or refractory multiple myeloma: analysis of the Optum electronic health records and commercial claims database, Clin Lymphoma Myeloma Leuk source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Baseline disease characteristics were generally balanced between treatment arms. 13”
What the sources say
- Supportedcites [13] Rodriguez-Otero, 2023, Ide-cel or standard regimens in relapsed and refractory multiple myeloma, N Engl J Med source
The Patients and Treatment section explicitly states that baseline characteristics were generally balanced between the ide-cel and standard-regimen groups. It notes an exception for Black race (7% versus 14%), consistent with the claim’s qualifier “generally.” (LLM, conf=0.95)
plainn = 386- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The median OS in the ide-cel (41.4 months) and SRs arms (37.9 months) were substantially longer than historical real-world data in TCE R/RMM (~9-22 months), 512 with longer than expected OS in the SRs arm, likely resulting from ide-cel treatment in patients who crossed over.”
What the sources say
- Not checked — no full text of the sourcecites [5] Chari, 25-27 2021 source
- Supportedcites [12] Moreau, 2023, MM-464 LocoMMotion: a prospective, observational, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma–final analysis at 2-year follow-up, Clin Lymphoma Myeloma Leuk source
The LocoMMotion Abstract reports real-life standard-of-care outcomes in triple-class-exposed patients with relapsed/refractory multiple myeloma. Its median overall survival of 13.8 months falls within the cited historical range of approximately 9–22 months and is shorter than either arm’s survival reported in the citing sentence. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a prespeci fi ed KarMMa-3 interim analysis (IA) with 18.6 months median follow-up, a single ide-cel infusion demonstrated signi fi cantly longer median PFS vs SRs (13.3 vs 4.4 months), with a 51% lower risk of disease progression or death (hazard ratio [HR], 0.49; 95% con fi dence interval [CI], 0.38-0.65; P < .0001). 13”
What the sources say
- Partly supportedcites [13] Rodriguez-Otero, 2023, Ide-cel or standard regimens in relapsed and refractory multiple myeloma, N Engl J Med sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Chimeric antigen receptor (CAR) T-cell therapy has shown promising ef fi cacy in patients with TCE R/RMM. 13-21”
What the sources say
- Supportedcites [13] Rodriguez-Otero, 2023, Ide-cel or standard regimens in relapsed and refractory multiple myeloma, N Engl J Med source
The Discussion identifies KarMMa-3 as a trial of CAR T-cell therapy in triple-class-exposed relapsed and refractory multiple myeloma. The Efficacy section reports a higher response rate with ide-cel than with standard regimens (71% versus 42%), supporting the claim of promising efficacy. (LLM, conf=0.93)
- Supportedcites [14] San-Miguel, 2023, Cilta-cel or standard care in lenalidomide-refractory multiple myeloma, N Engl J Med source
The Efficacy section (p. 5) reports a lower risk of progression or death with cilta-cel than with standard care, with similar effects in the triple-class-refractory subgroup. Those patients had necessarily been exposed to all three drug classes. The trial population was specifically lenalidomide-refractory and had received one to three prior lines of therapy. (LLM, conf=0.88)
- Supportedcites [15] Sidana, 2019, CAR T-cell therapy: is it prime time in myeloma?, Blood Adv source
The Abstract (p.1) states 'Early clinical studies have shown promising response rates in heavily pretreated patients,' and the Introduction frames the target population as patients 'refractory to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibody' (i.e., triple-class-exposed), concluding that 'CAR T-cell therapy has emerged as a promising treatment for relapsed and refractory MM.' Table 1 (Introduction) reports high ORRs (e.g., 81-100% in BCMA trials) in cohorts with median 3-11 prior lines, matching the claim's population and magnitude. The paper is a review reporting others' trial results rather than an original study, but the paraphrase does not attribute primary data to it. (LLM, conf=0.85)
- Supportedcites [16] Martin, 2023, Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up, J Clin Oncol source
The Methods passage says eligible patients had relapsed/refractory multiple myeloma and prior exposure to a proteasome inhibitor, immunomodulatory drug, and anti-CD38 therapy—the three classes in the claim. The Results > Efficacy passage reports a 97.9% overall response rate after cilta-cel CAR T-cell therapy, supporting the characterization of its efficacy as promising. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [17] Agha, 2021, CARTITUDE-2: efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy, J Clin Oncol source
- Supportedcites [18] Munshi, 2021, Idecabtagene vicleucel in relapsed and refractory multiple myeloma, N Engl J Med source
The Discussion reports frequent and deep responses to ide-cel, a CAR T-cell therapy, in patients with triple-class-exposed relapsed and refractory myeloma. It reports a response in 73% of treated patients and a complete response or better in 33%, supporting the claim of promising efficacy. (LLM, conf=0.94)
- Supportedcites [19] Raje, 2019, Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma, N Engl J Med source
The Results—Patients section reports that 79% of participants had been exposed to proteasome inhibitors, immunomodulatory drugs, and daratumumab, consistent with triple-class exposure. Results—Efficacy reports an 85% objective response rate to bb2121 CAR T-cell therapy in the relapsed or refractory myeloma cohort. The claim says the therapy has shown promising efficacy in this population; it does not assert that every participant was triple-class exposed. Page numbers were not available in our copy. (LLM, conf=0.90)
- Supportedcites [20] Jagannath, 2021, KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma, Blood Cancer J source
The Discussion (page not available in our copy) reports significantly improved responses and survival with ide-cel, a CAR T-cell therapy, compared with real-world treatment in triple-class-exposed relapsed and refractory multiple myeloma. It calls ide-cel a promising treatment option for this population. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [21] van de Donk, 2022, Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B, J Clin Oncol source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
36 more claims · 2 with their cited sources checked
Create a free account to see all 80 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 35
- The quote only partly states this claim. 1
- Probably not a substantial claim. 6
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
Cited work 10.1016/j.clml.2022.01.005 · retracted 2022-01-10 · notice 10.1016/j.clml.2022.01.005 · this paper published 2024-12-05
Citations
Cites
1 retracted
Dimopoulos, M. A., Richardson, P. G. G., & Lonial, S. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.01.005
RetractedAaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationAnti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
Self-citationCilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303379 · Cited by 827
Self-citationIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213614 · Cited by 781
Self-citationMartin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663
Self-citationOutcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Self-citation
Research works printed but not linked: 2
- 2010, Common Terminology Criteria for Adverse Events (CTCAE) v4. 03
- 2018, Question and Answer on Adjustment for Cross-Over in Estimating Effects in Oncology Trials
Cited by
Dimopoulos, M. A., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M.-V., Zweegman, S., Cook, G., Engelhardt, M., Delforge, M., Hajek, R., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01041-x · Cited by 165
“These decisions were based on the results of the phase III KarMMa-3 trial 117,118 in which 386 patients with RRMM who had received two to four prior lines of therapy (with the characteristics previously described) were randomly assigned (2:1) to receive either ide-cel (at a dose range of 150 × 10 6…”
Self-citationCAR-T cell therapy in Multiple Myeloma: current status and future challenges
Swan, D., Madduri, D., & Hocking, J. S. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01191-8 · Cited by 121
New horizons in our understanding of precursor multiple myeloma and early interception
dos Santos, D. M. C., Toenges, R., Bertamini, L., Alberge, J.-B., & Ghobrial, I. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00755-x · Cited by 36
“With the advent of next-generation”
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma
Paiva, B., Shi, Q., Puig, N., Cedena, M., Órfão, A., Durie, B. G. M., Munshi, N. C., & Miguel, J. F. S. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01017-x · Cited by 41
“GPRC5D-targeted T cell-redirecting immunotherapies has resulted in substantially increased CR rates in patients with relapsed and/or refractory MM (RRMM), thereby creating momentum to also assess MRD in this setting 37,68,69 .”
van de Donk, N. W. C. J., Moreau, P., Miguel, J. F. S., Mateos, M., Dimopoulos, M. A., Zweegman, S., Gay, F., Engelhardt, M. M., Mina, R., Zamagni, E., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00117-6 · Cited by 33
Self-citation
Metadata
- Authors
- Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., Moreau, P., Solomon, S., Abrahamsen, I. W., Baz, R., Broijl, A., Chen, C., Jagannath, S., Raje, N., Scheid, C., Delforge, M., Benjamin, R., Pabst, T., Iida, S., Berdeja, J., Giralt, S., Truppel-Hartmann, A., Chen, Y., Zhong, X., Wu, F., Piasecki, J., Eliason, L., Dhanda, D., Felten, J., Caia, A., Cook, M., Popa McKiver, M., & Rodríguez-Otero, P.
- Affiliations
- Mayo Clinic in Florida (US)
- Université Paris Cité (FR)
- The University of Texas MD Anderson Cancer Center (US)
- 4Department of Medical and Surgical Sciences, Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
- Emory University (US)
- Université de Lille (FR)
- University of Wisconsin–Madison (US)
- University of Alabama at Birmingham (US)
- Washington University in St. Louis (US)
- University of Calgary (CA)
- Centre Hospitalier Universitaire de Nantes (FR)
- Northside Hospital (US)
- Oslo University Hospital (NO)
- Moffitt Cancer Center (US)
- Erasmus MC Cancer Institute (NL)
- Princess Margaret Cancer Centre (CA)
- Tisch Cancer Institute (US)
- Massachusetts General Hospital (US)
- University of Cologne (DE)
- Universitair Ziekenhuis Leuven (BE)
- King's College Hospital (GB)
- University Hospital of Bern (CH)
- Nagoya City University (JP)
- Sarah Cannon (US)
- Memorial Sloan Kettering Cancer Center (US)
- 262seventy bio, Cambridge, MA
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (Switzerland) (CH)
- 27Bristol Myers Squibb, Princeton, NJ
- 29Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain
- Corresponding author
- Ailawadhi, Sikander
- ORCID
- Ailawadhi, Sikander
- Arnulf, Bertrand
- Patel, Krina
- Nooka, Ajay K.
- Manier, Salomon
- Callander, Natalie
- Costa, Luciano J.
- Bahlis, Nizar J.
- Moreau, Philippe
- Solomon, Scott
- Abrahamsen, Ingerid Weum
- Baz, Rachid
- Broijl, Annemiek
- Chen, Christine
- Jagannath, Sundar
- Raje, Noopur
- Scheid, Christof
- Delforge, Michel
- Benjamin, Reuben
- Pabst, Thomas
- Iida, Shinsuke
- Berdeja, Jesús
- Giralt, Sergio
- Truppel-Hartmann, Anna
- Chen, Yanping
- Zhong, Xiaobo
- Wu, Fan
- Piasecki, Julia
- Eliason, Laurie
- Dhanda, Devender
- Cook, Mark
- Rodríguez-Otero, Paula
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2024-12-05
- Volume
- 144
- Issue
- 23
- Pages
- 2389-2401
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W4401942365
- Cited by
- 79
- References
- 29
- Citations by year
- 2026: 40 · 2025: 34 · 2024: 5
- FWCI
- 24.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Blood (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- HAL (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by-nc-nd)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- American Society of Clinical Oncology
- Celgene
- National Cancer Research Institute
- Regeneron Pharmaceuticals
- BeiGene
- Chugai Pharmaceutical
- Pharmacyclics
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- idecabtagene vicleucel, relapsed/refractory multiple myeloma, CAR T-cell therapy, progression-free survival, overall survival, crossover, patient-reported outcomes, prior lines of therapy, complete response, safety signals, benefit-risk profile, CAR T cell manufacturing
- MeSH terms
- Receptors, Chimeric Antigen, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Immunotherapy, Adoptive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. https://app.cochat.ai/papers/10.1182/blood.2024024582
- The paper
- Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., Moreau, P., Solomon, S., Abrahamsen, I. W., Baz, R., Broijl, A., Chen, C., Jagannath, S., Raje, N., Scheid, C., . . . Rodríguez-Otero, P. (2024). Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood. https://doi.org/10.1182/blood.2024024582
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.